<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<STUDY_SET>
    <STUDY alias="DRP009358" center_name="NCCRI" accession="DRP009358">
        <IDENTIFIERS>
            <PRIMARY_ID label="BioProject ID">PRJDB12182</PRIMARY_ID>
        </IDENTIFIERS>
        <DESCRIPTOR>
            <STUDY_TITLE>Pro-tumor function and regulatory landscape of PD-L2 in B-cell lymphoma</STUDY_TITLE>
            <STUDY_TYPE existing_study_type="Other"/>
            <STUDY_ABSTRACT>Unlike PD-L1, little is known about the biological relevance and regulatory mechanism of PD-L2, another PD-1 ligand, in cancer. We constructed single-cell transcriptomic, surface phenotypic, and T/B-cell receptor repertoire maps of nonmalignant cells from mock-, Pd-l1-, and Pd-l2-expressing murine tumors. In addition, we identified a novel PD-L2 exon and performed CAGE-seq to precisely characterize the transcriptional start site.</STUDY_ABSTRACT>
            <CENTER_PROJECT_NAME>Pro-tumor function and regulatory landscape of PD-L2 in B-cell lymphoma</CENTER_PROJECT_NAME>
            <RELATED_STUDIES>
                <RELATED_STUDY>
                    <RELATED_LINK>
                        <DB>bioproject</DB>
                        <ID>PRJDB12182</ID>
                        <LABEL>PRJDB12182</LABEL>
                    </RELATED_LINK>
                    <IS_PRIMARY>true</IS_PRIMARY>
                </RELATED_STUDY>
            </RELATED_STUDIES>
            <STUDY_DESCRIPTION>Unlike PD-L1, little is known about the biological relevance and regulatory mechanism of PD-L2, another PD-1 ligand, in cancer. We constructed single-cell transcriptomic, surface phenotypic, and T/B-cell receptor repertoire maps of nonmalignant cells from mock-, Pd-l1-, and Pd-l2-expressing murine tumors. In addition, we identified a novel PD-L2 exon and performed CAGE-seq to precisely characterize the transcriptional start site.</STUDY_DESCRIPTION>
        </DESCRIPTOR>
    </STUDY>
</STUDY_SET>
